Navigation Links
Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey
Date:12/3/2008

SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced an exclusive, binding letter of intent with EIP Eczacibasi Ilac Pazarlama A.S. (EIP) for sales and marketing of the company's Allovectin-7(R) immunotherapeutic product candidate in Turkey and the Turkish Republic of Northern Cyprus. EIP has agreed to obtain the necessary regulatory approvals for the territory and to pay Vical upfront and milestone payments plus a specified transfer price in exchange for the rights to an exclusive license for the territory. EIP is a leading Turkish pharmaceutical company and has multiple licensing agreements with major biotech and pharmaceutical companies including Amgen, Pfizer, Procter & Gamble, and sanofi-aventis.

Vijay B. Samant, Vical's President and Chief Executive Officer, said, "As we advance toward completion of enrollment in our Phase 3 trial of Allovectin-7(R) in patients with advanced metastatic melanoma, we are also looking ahead to commercialization opportunities in key global markets. As an established pharmaceutical company in Turkey with a significant cancer franchise, EIP has the expertise to guide Allovectin-7(R) through the Turkish approval process and the strength to launch and sell Allovectin-7(R) successfully in the Turkish market. We continue to explore licensing and distribution agreements in additional international markets."

About Allovectin-7(R)

Allovectin-7(R) is a plasmid/lipid complex containing the DNA sequences encoding HLA-B7 and beta-2 microglobulin, which together form a Class I Major Histocompatibility Complex, or MHC-I antigen. Injection of Allovectin-7(R) directly into tumors is designed to stimulate an immune response against both local and distant metastatic tumors. Vical conducted a large Phase 2 trial evaluating Allovectin-7(R) immunothera
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
2. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
3. U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vicals Vaxfectin(R) Adjuvant
4. Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
5. First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease
6. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
7. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
8. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
9. Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
10. Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial
11. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... September 2, 2015 The ... global clinical trials review of H2, 2015 provides ... an objective to enhance decision making capabilities of ... report on Keratoconus market clinical trials review spread ... institutes / government organizations and supported with 43 ...
(Date:9/1/2015)... BRISBANE, Australia and Delaware , ... -- Invion Limited (ASX: IVX; "Company" or "Invion"), is pleased ... issue the following securities to an institutional investor in ... for aggregate gross proceeds of approximately A$1.001 million ("Placement") by ... an issue price of $0.014 per share. ...
(Date:9/1/2015)... 1, 2015 Ardelyx, Inc. (NASDAQ: ... gastrointestinal and cardio-renal diseases, today announced that Sanofi ... and license agreement for Ardelyx,s portfolio of NaP2b ... payment associated with termination and the return of ... Sanofi entered into an option and license agreement ...
Breaking Medicine Technology:Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 2Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 3Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 4Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 5Invion Announces Private Placement to US Institutional Investor 2Invion Announces Private Placement to US Institutional Investor 3Ardelyx Regains NaP2b Program from Sanofi 2Ardelyx Regains NaP2b Program from Sanofi 3
... Complete,Genomics Inc., a newly launched, third-generation human ... (ISB) today announced their,partnership to conduct populationwide human ... project, Complete Genomics will use its proprietary,DNA sequencing ... by,ISB. Then, once proof-of-concept has been demonstrated, ISB ...
... 6 Dendreon Corporation (Nasdaq:,DNDN) will host a ... 9:00 AM,ET (6:00 AM PT) to review the ... for Prostate AdenoCarcinoma Treatment, also known as D9902B),clinical ... immunotherapy for the treatment of advanced prostate,cancer., ...
Cached Medicine Technology:Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study 2Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2
(Date:9/2/2015)... ... September 02, 2015 , ... ... content, records and case management solutions and services to both government and commercial ... Re-sizing and Image Clean-up utility for IBM’s Datacap document capture platform. EDAC ...
(Date:9/2/2015)... ... September 02, 2015 , ... Available ... marine cosmetics introduces PIONNIÈRE XMF Perfection Youth Rich Cream , an evolution ... biotechnological anti-aging power with a lipid-replenishing marine oil for intense nourishing and moisturizing. ...
(Date:9/2/2015)... ... September 02, 2015 , ... Dr. Robert G. Schwartz , ... now certified in “Systema”: a Russian martial art system that is also a philosophy ... Systema , which dates back to the 10th century, is a Russian Martial ...
(Date:9/1/2015)... ... September 01, 2015 , ... An August 25 ... plastic surgeries conducted each year on teenagers, quoting a New York City-area plastic ... Hills-based plastic surgeon Payam Jarrah-Nejad, M.D., F.I.C.S., F.A.C.S., known more familiarly to patients ...
(Date:9/1/2015)... ... September 02, 2015 , ... The Journal of Pain Research ... in the USA ”. , As corresponding author Mr Christopher Malone says “Migraine headache ... our study, we endeavoured to better understand how migraine headaches impact the lives of ...
Breaking Medicine News(10 mins):Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 2Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 3Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 4Health News:Dr. Robert G. Schwartz Achieves Certification in Russian Martial Art “Systema” and Focuses on Integrating Techniques & Principles into Health Care Delivery 2Health News:Dr. Robert G. Schwartz Achieves Certification in Russian Martial Art “Systema” and Focuses on Integrating Techniques & Principles into Health Care Delivery 3Health News:Teen Plastic Surgery Article Understates the Most Important Realities of Procedures on Young People, Notes Dr. J 2Health News:Migraine, treatment, comorbidities, and quality of life published by Dove Medical Press 2
... France June 04, 2009 The cause of ... after Alzheimer,s disease, is unknown, but in most cases ... risk factors and genetic susceptibility. Laboratory studies in rats ... an animal model of PD and several epidemiological studies ...
... BioTrends Research Group, Inc. announces the release of the baseline ... The survey was completed by U.S. Rheumatologists in May 2009, ... , Once monthly dosing seems to be playing well, according ... of SIMPONI. 84% of the Rheumatologists surveyed report that they ...
... Pa., June 4 Herley Industries, Inc. (Nasdaq: ... Israel, has recently received contracts valued at approximately $4 million ... customer. These are follow-on awards for an existing customer ... to a U.S. aircraft. , , Herley Industries, Inc. ...
... The Cardiovascular Nurse and Technologist Symposium at TCT 2009 ... clinical/administrative strategies for the management of the cardiovascular patient: ... receiving PCI, Revascularization decisions, Management decisions regarding patients with ... charge of your own health WHEN: ...
... uninterrupted supply for customers , , LAKE ZURICH, Ill., ... improving blood collection, safety and availability for patient care, said ... a patent lawsuit brought by Haemonetics Corporation in 2005. ... , , In conjunction with this litigation, ...
... , For Father,s Day, Forget The Usual With A Gift ... Physician Formulated Anti-Wrinkle Moisturizer , , PACIFIC PALISADES, Calif., ... This year, give Dad something he secretly desires but may ... the best for the family hero. Dermagenics Physician-Formulated ...
Cached Medicine News:Health News:Association found between Parkinson's disease and pesticide exposure in French farm workers 2Health News:Once Monthly Dosing: How Much of a Competitive Advantage is it? Rheumatologists Provide Insight in the Baseline Report of LaunchTrends(TM): SIMPONI(TM) 2Health News:Herley's Israeli Subsidiary, GMI Eyal, is Selected to Provide Complex Microwave Switch Assemblies for a U.S. Customer 2Health News:Nurses: Providing angioplasty patient care in and out of the cath lab 2Health News:Fenwal Statement Regarding Patent Litigation 2Health News:SHOW DAD YOU LOVE HIS FACE 2
... Osteopal V is a low viscosity bone ... in vertebroplasty. The bone cement is injected ... purposes. Osteopal V is used for the ... of zirconium dioxide is included in the ...
Based on the trusted Schaltenbrand-Wahren Atlas for Stereotaxy of the human brain, Atlasplan Software provides anatomical detail of the basal ganglia region of the brain and can help confirm target a...
... a comprehensive platform for standard neurosurgical ... to plan the optimal surgical path ... Combined with unique features such as ... planning tool, Neurosight becomes a very ...
3D Cranial is the most widely used surgical navigation software. Navigate with confidence and ease with our displayed Zone of Accuracy and several fully automated features. 3D Cranial offers seamless...
Medicine Products: